Sophiris Bio Inc. (NASDAQ:SPHS) shares traded down 6.9% during trading on Tuesday . The company traded as low as $4.88 and last traded at $5.11, with a volume of 2,203,446 shares. The stock had previously closed at $5.49.

A number of research analysts have commented on the company. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a report on Friday, June 10th. Echelon Wealth Partners reaffirmed a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a report on Friday, June 10th.

The company’s market cap is $105.95 million. The firm has a 50 day moving average price of $2.99 and a 200 day moving average price of $1.89.

Sophiris Bio (NASDAQ:SPHS) last posted its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. On average, equities analysts predict that Sophiris Bio Inc. will post ($0.73) earnings per share for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.